UBS Group
ABMD

UBS Group’s Abiomed Inc ABMD Stock Holding History

UBS Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$33K – 8341
2018
Q4 		$33K Sell
100
-1,100
-92% -$382K ﹤0.01% 6423
2018
Q3 		$540K Buy
1,200
+900
+300% +$355K ﹤0.01% 4346
2018
Q2 		$123K Buy
+300
New +$109K ﹤0.01% 5294
2015
Q2 		– Sell
-200
Closed -$14K – 8952
2015
Q1 		$14K Hold
200
– – ﹤0.01% 7375
2014
Q4 		$8K Buy
+200
New +$6.31K ﹤0.01% 8630

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's ABMD Position: Q4 2022 in Review

UBS Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 35,053 shares — an estimated $8.61M sold.

UBS Group first reported a position in ABMD in Q4 2014 and held it in 32 quarters. The position peaked at $39.5M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • UBS Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 35,053 Abiomed Inc shares in Q4 2022, an estimated $8.61M.
  • UBS Group first reported a position in Abiomed Inc in Q4 2014 and held it in 32 quarters.
  • UBS Group's Abiomed Inc position peaked at $39.5M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.